Press Releases

Adamis Pharmaceuticals to Present at Conferences in June 2019

SAN DIEGO, May 29, 2019 — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that management is scheduled to present a company overview at two upcoming conferences in June 2019. During the conferences, management from Adamis will discuss the company’s business, regulatory and operational developments.

Details of the conference presentations are as follows:

Event: 9th Annual LD Micro Invitational Conference
Date: Tuesday, June 4, 2019
Time: 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time)
Location: Luxe Hotel in Los Angeles, California
Event: Raymond James Life Sciences and MedTech Conference
Date: Tuesday, June 18, 2019
Time: 10:15 a.m. Pacific Time (1:15 p.m. Eastern Time)
Location: Lotte New York Palace, New York, New York

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company’s SYMJEPITM (epinephrine) Injection 0.3mg and SYMJEPITM (epinephrine) Injection 0.15mg products were approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis previously announced a distribution and commercialization agreement with Sandoz, a division of Novartis Group, to market Symjepi in the U.S. Adamis is developing additional products, including a naloxone injection product candidate for the treatment of opioid overdose, a sublingual tadalafil product candidate for the treatment of erectile dysfunction, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for use by hospitals, clinics and surgery centers throughout most of the United States.

Adamis Contacts

Mark Flather
Senior Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com

Primary Logo

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.